Valuation: Norda ASA

Market Cap 513M 53.1M 46.68M 43.46M 39.91M 74.94M 5.09B 75.93M 517M 202M 2.51B 199M 195M 8.69B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.35M 24.05M 22.39M 20.56M 38.6M 2.62B 39.11M 266M 104M 1.3B 103M 100M 4.48B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.65%
6 months+6.67%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 46.28M
+2.08%-0.99%-1.03%+11.57% 46.86B
-0.70%+4.34%+405.14%+647.78% 40.23B
+0.34%+5.37%+11.12%+56.21% 36.23B
+1.64%+3.85%+7.07%-5.70% 34.72B
+0.62%+1.65%+5.41%+43.89% 27.89B
-0.77%+13.11%+31.80%+139.92% 16.79B
+0.01%+1.30% - - 16.74B
+0.78%-5.88%+2.29%+7.76% 13.12B
+1.38%+1.75%-10.84%-30.02% 12.7B
Average +0.66%+1.02%+51.00%+109.13% 24.53B
Weighted average by Cap. +0.63%+1.05%+76.45%+138.85%

Financials

2023 2024
Net sales 86.92M 8.99M 7.91M 7.36M 6.76M 12.69M 863M 12.86M 87.49M 34.17M 426M 33.76M 33.04M 1.47B 372M 38.48M 33.83M 31.49M 28.92M 54.3M 3.69B 55.02M 374M 146M 1.82B 144M 141M 6.3B
Net income 31.17M 3.23M 2.84M 2.64M 2.42M 4.55M 309M 4.61M 31.38M 12.25M 153M 12.11M 11.85M 528M 126M 13.03M 11.46M 10.67M 9.79M 18.39M 1.25B 18.63M 127M 49.51M 617M 48.92M 47.87M 2.13B
Net Debt -311M -32.21M -28.31M -26.36M -24.2M -45.45M -3.09B -46.05M -313M -122M -1.53B -121M -118M -5.27B -249M -25.75M -22.63M -21.07M -19.35M -36.34M -2.47B -36.81M -250M -97.82M -1.22B -96.65M -94.57M -4.21B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock